Jeffrey N. Simmons

President and Chief Executive Officer at Elanco Animal Health Inc

Board

Since N/A

Age

55 years

Tenure

Has been serving as the President and Chief Executive Officer of ELAN and has signed multiple financial reports including the FY 2024 10-K on February 25, 2025, although further details of his tenure remain unspecified.

Also at Elanco Animal Health Inc

JMM

James M. Meer

Senior Vice President, Chief Accounting Officer

Shiv O’Neill

Executive Vice President, General Counsel and Corporate Secretary

TSY

Todd S. Young

Executive Vice President and CFO

About

Jeffrey N. Simmons is the President and Chief Executive Officer of ELAN, serving in this capacity as confirmed by his signature on key financial reports including the FY 2024 10-K filed on February 25, 2025. At 55 years old, he provides executive leadership for the company, overseeing a critical period in ELAN’s financial reporting and performance.

Despite his prominent role, detailed information regarding his personal background, education, or the exact timeline when he joined ELAN is not available in the documents. The available data focuses primarily on his executive function and the documentation he endorses, without providing further insight into his earlier career or academic achievements.

His consistent presence in the company’s filings over the past few fiscal years underlines his ongoing commitment to ELAN. While details such as his start date or any prior positions within ELAN remain unspecified, his responsibility as CEO is well established by the regular reporting and disclosures he has signed, reflecting his key role in the company’s strategic oversight.

$ELAN Performance Under Jeffrey N. Simmons

Past Roles

Organization	Role	Date Range	Details
Eli Lilly and Company	Senior Vice President & President, Elanco Animal Health division	2008–2018	Held a top leadership role within the animal health division, later transitioning to CEO of ELAN
Eli Lilly and Company	International Marketing Manager, Elanco Animal Health division	N/A	Leadership role in global marketing of the animal health division
Eli Lilly and Company	Country Director for Brazil, Elanco Animal Health division	N/A	Managed operations in Brazil as part of global expansion strategies
Eli Lilly and Company	Area Director for Western Europe, Elanco Animal Health division	N/A	Directed regional strategies in Western Europe
Eli Lilly and Company	Executive Director for U.S. and Global Research & Development, Elanco Animal Health division	N/A	Oversaw research and development initiatives across U.S. and global markets

External Roles

null

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Salary	$1,200,000	2023 Annual	Fixed base salary for 2023
All Other Compensation	$30,761	2023 Annual	Total additional fixed payments; detailed breakdown not provided

Performance Compensation

Data from FY 2023

Performance Awards (PAs) for 2023

Metric (Unit)	Value
Performance Metric [Description]**	Adjusted EBITDAR
Target (# of shares)	497,336 shares
Threshold	Not provided
Maximum (# of shares)	994,672 shares
Payout Range	0% to 200% of target
Vesting Schedule	Two-year performance period (Jan 1, 2023 to Dec 31, 2024) with vesting/payout in Feb 2025
Evaluation Period	2023 and 2024
Grant Date	March 1, 2023
Approval Date	February 24, 2023
Grant Date Fair Value	$5,600,003
Grant Date Stock Price	$11.26 per share
Conditions/Other Details	Must remain employed through the performance period; no dividends accrue; final payout obtained by averaging payout multiples for both performance years

This table summarizes the performance compensation components for Jeffrey N. Simmons for 2023.